Cincinnati Man Fights rare disease | Experimental Treatment Offers New Hope
Michael Lomonaco shares his story with Cincinnati’s Local 12 News as he battles a rare disease and pursues an experimental treatment offering new hope.
AL Amyloidosis Patient Disease-Free After NXC-201 CAR-T Treatment | IMMX
After living with AL amyloidosis for 18 months and exhausting available treatment options, Peter received investigational CAR-T therapy at Memorial Sloan Kettering Cancer Center and is now reported to be disease free.
Father among first to receive potentially life saving NXC-201 treatment for rare disease
A father battling rare and life-threatening AL amyloidosis is among the patients receiving NXC-201, an investigational CAR-T therapy being developed by Immix Biopharma (NASDAQ: IMMX)
Safety and efficacy of NXC-201, an anti-BCMA CAR-T, in R/R AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses findings from a Phase I/II trial (NCT04720313) investigating NXC-201, an anti-BCMA CAR-T product, in the treatment of heavily pretreated relapsed/refractory (R/R) light chain (AL) amyloidosis.
Good Day New York : Dr. Landau & NYC Patient July 20
Heather Landau of Memorial Sloan Kettering Cancer Center alongside Peter, an MSK patient. Peter explains that he had lived with AL amyloidosis for about 18 months and had exhausted the available treatment options. He then received an investigational CAR T-cell therapy at MSK and is now described as disease-free.
HEALTH MATTERS: Local Woman Shares Rare Diagnosis & Breakthrough Treatment (CAR-T Cell Therapy)
Sacramento-area resident Lisa Ferrero, was only given 5 years to live before she participated in a clinical trial exploring CAR-T`s potential for treating her rare disease, where 95% of conditions still have no FDA-approved treatment.
How CAR T Cell Therapy Eliminated a Patient’s Rare Blood Disease and Restored Her Strength
For 20+ years, Maureen lived with light chain (AL) amyloidosis, a rare and relentless blood disease. Then came a scientific breakthrough years in the making.
Biotech Breakthrough: The $450K Treatment That Could Save 30,000 Lives | IMMX CEO & CFO Interview
In this exclusive Stocktwits executive interview, Katie Perry sits down with Dr. Ilya Rachman (CEO) and Gabriel Morris (CFO) of IMMX (Immix Biopharma) to uncover how they’re racing toward FDA approval for a revolutionary therapy targeting relapsed/refractory AL amyloidosis, a rare, deadly disease with no current approved treatments.